Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism

Br J Cancer. 2023 Nov;129(10):1546-1557. doi: 10.1038/s41416-023-02412-w. Epub 2023 Sep 9.

Abstract

Fumarate hydratase (FH) is an enzyme of the Tricarboxylic Acid (TCA) cycle whose mutations lead to hereditary and sporadic forms of cancer. Although more than twenty years have passed since its discovery as the leading cause of the cancer syndrome Hereditary leiomyomatosis and Renal Cell Carcinoma (HLRCC), it is still unclear how the loss of FH causes cancer in a tissue-specific manner and with such aggressive behaviour. It has been shown that FH loss, via the accumulation of FH substrate fumarate, activates a series of oncogenic cascades whose contribution to transformation is still under investigation. In this review, we will summarise these recent findings in an integrated fashion and put forward the case that understanding the biology of FH and how its mutations promote transformation will be vital to establish novel paradigms of oncometabolism.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell* / genetics
  • Carcinoma, Renal Cell* / pathology
  • Female
  • Fumarate Hydratase / genetics
  • Humans
  • Kidney Neoplasms* / genetics
  • Kidney Neoplasms* / pathology
  • Neoplastic Syndromes, Hereditary* / genetics
  • Skin Neoplasms* / genetics
  • Uterine Neoplasms* / genetics

Substances

  • Fumarate Hydratase